The data available to US Preventive Services Task Force didn’t address an important question: what do you recommend to African American men who are twice as likely to develop prostate cancer and die from it as the general population?
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
